Abstract 4912
Background
AK104 is a tetravalent bispecific human IgG1 antibody, targeting two clinically validated receptors, PD-1 and CTLA-4. This bispecific antibody is designed based on Akeso Tetrabody platform (AACR, 2018). AK104 introduces novel T cell targeting MOAs that may provide an improved therapeutic index and a favorable toxicity profile when compared to the PD-1 and CTLA-4 combinations. In addition, we have shown increased avidity of AK104 binding to PD-1 and CTLA-4 compared to the combinations. The combination therapy with anti-PD-1 and anti-CTLA-4 agents is approved by FDA for metastatic melanoma, renal cell carcinoma and MSI-H/dMMR colorectal cancer. The efficacy of these drug combinations is dose dependent, and the toxicity associated with anti-CTLA-4 agents in particular is dose limiting, thereby potentially limiting full potential for combination therapy. Despite recent advances, the prognosis of patients with advanced gastric cancer remains poor. AK104 may show improved efficacy and safety in comparison to the combination of conventional anti-PD-1/L1 and anti-CTLA-4 antibodies.
Trial design
This multicenter, open-label, phase Ib/II study will evaluate the safety and efficacy of AK104 in combination with oxaliplatin and capecitabine (mXELOX) as first-line therapy in patients with advanced gastric or GEJ adenocarcinoma. The dose-escalation phase will evaluate three dose levels (4mg/kg, 6mg/kg, and 10mg/kg Q2W) to identify a maximum tolerated dose (MTD). Selected cohorts will be expanded up to a total of 18 patients per cohort to further establish the recommended Phase 2 dose (RP2D). Dose escalation and expansion phase will be followed by dose confirmation phase (Phase II) which will further characterize the treatment of AK104 in combination at RP2D. The primary endpoints are safety and efficacy (ORR in Phase II). Secondary endpoints include additional efficacy (PFS, DoR), pharmacokinetics, PD and immunogenicity. Exploratory endpoints include efficacy according to immune-related RECIST and correlations between potential biomarkers (PD-L1 expression, TMB) and clinical activity.
Clinical trial identification
NCT03852251.
Editorial acknowledgement
Legal entity responsible for the study
Peking University Cancer Hospital & Institute, Beijing, China.
Funding
Akeso Biopharma, Inc., Zhongshan, China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2083 - PALAESTRA - A phase II trial with short-course radiotherapy followed by chemotherapy as palliative treatment in esophageal adenocarcinoma
Presenter: David Borg
Session: Poster Display session 2
Resources:
Abstract
4317 - Prognostic factors analysis of 343 patients with adenocarcinoma of esophagogastric junction
Presenter: Yixun Lu
Session: Poster Display session 2
Resources:
Abstract
4099 - Effects of preoperative preparation time on efficacy of neoadjuvant chemotherapy (SOX) in patients with advanced gastric cancer
Presenter: Xinxin Wang
Session: Poster Display session 2
Resources:
Abstract
3769 - The prognostic value of higher absolute lymphocyte counts for patients with surgically resected non-advanced gastric cancer
Presenter: Se Jun Park
Session: Poster Display session 2
Resources:
Abstract
1718 - Trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy in resectable HER2+ esophageal adenocarcinoma patients: an update on survival and predictive biomarkers in the TRAP study
Presenter: Charlotte Stroes
Session: Poster Display session 2
Resources:
Abstract
5403 - Interim analysis of a phase II trial of perioperative chemotherapy plus avelumab in esophagogastric and gastric adenocarcinoma
Presenter: Thierry Alcindor
Session: Poster Display session 2
Resources:
Abstract
591 - Evaluation of the introduction of primary G-CSF prophylaxis to the FLOT chemotherapy regimen.
Presenter: Kelly-Marie Crampton
Session: Poster Display session 2
Resources:
Abstract
1402 - Subgroup analyses of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer
Presenter: Tsutomu Hayashi
Session: Poster Display session 2
Resources:
Abstract
3743 - HER2 Copy Number as Predictor of Disease-Free Survival in HER2-Positive Resectable Gastric Cancer
Presenter: Zimin Liu
Session: Poster Display session 2
Resources:
Abstract
2032 - Effect of neoadjuvant chemotherapy on the Programmed Death-1 pathway in esophageal and gastric cancer
Presenter: Maria Svensson
Session: Poster Display session 2
Resources:
Abstract